Edition:
United States

Glaukos Corp (GKOS.N)

GKOS.N on New York Stock Exchange

40.88USD
22 Jun 2018
Change (% chg)

$0.23 (+0.57%)
Prev Close
$40.65
Open
$40.70
Day's High
$41.11
Day's Low
$40.50
Volume
598,890
Avg. Vol
127,005
52-wk High
$45.00
52-wk Low
$23.10

Chart for

About

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision... (more)

Overall

Beta: --
Market Cap(Mil.): $1,426.96
Shares Outstanding(Mil.): 34.91
Dividend: --
Yield (%): --

Financials

  GKOS.N Industry Sector
P/E (TTM): -- 41.65 34.14
EPS (TTM): -0.11 -- --
ROI: -2.75 14.42 13.10
ROE: -2.77 17.62 15.09

BRIEF-Glaukos Q1 Loss Per Share $0.08

* GLAUKOS CORP ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 09 2018

BRIEF-Glaukos Q4 Earnings Per Share $0.03

* ORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 28 2018

BRIEF-Glaukos' Idose Travoprost Achieves Sustained IOP Reduction And Favorable Safety Profile In 12-Month Interim Cohort

* GLAUKOS CORPORATION’S IDOSE™ TRAVOPROST ACHIEVES SUSTAINED IOP REDUCTION AND FAVORABLE SAFETY PROFILE IN 12-MONTH INTERIM COHORT

Jan 10 2018

BRIEF-Glaukos Submits IDE Application To FDA To Study iStent Infinite Trabecular Micro-Bypass System

* GLAUKOS SUBMITS IDE APPLICATION TO FDA TO STUDY ISTENT INFINITE™ TRABECULAR MICRO-BYPASS SYSTEM

Jan 03 2018

Competitors

Earnings vs. Estimates